A share price of Coya Therapeutics Inc [COYA] is currently trading at $7.2, up 18.81%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The COYA shares have gain 12.68% over the last week, with a monthly amount glided 26.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Coya Therapeutics Inc [NASDAQ: COYA] stock has seen the most recent analyst activity on July 09, 2025, when Lake Street initiated its Buy rating and assigned the stock a price target of $16. Previously, D. Boral Capital started tracking the stock with Buy rating on December 04, 2024, and set its price target to $15.
Coya Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.65 and $10.24. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Coya Therapeutics Inc [NASDAQ: COYA] shares were valued at $7.2 at the most recent close of the market. An investor can expect a potential return of 150.0% based on the average COYA price forecast.
Analyzing the COYA fundamentals
Trailing Twelve Months sales for Coya Therapeutics Inc [NASDAQ:COYA] were 0.42M which represents -95.22% decline. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -15186.43%, Pretax Profit Margin comes in at -14428.89%, and Net Profit Margin reading is -14427.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.86 and Total Capital is -0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Coya Therapeutics Inc [NASDAQ:COYA] is 7.43. As well, the Quick Ratio is 7.43, while the Cash Ratio is 6.61. Considering the valuation of this stock, the price to sales ratio is 286.80, the price to book ratio is 4.25.
Transactions by insiders
Recent insider trading involved SNYDER DAVID S, Chief Financial Officer, that happened on Nov 14 ’24 when 1800.0 shares were purchased. Chief Executive Officer, Swaminathan Arun completed a deal on Nov 13 ’24 to buy 5000.0 shares. Meanwhile, Chief Medical Officer Grossman Fred bought 2710.0 shares on Nov 11 ’24.
